

# UC San Diego

## UC San Diego Previously Published Works

### Title

Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer.

### Permalink

<https://escholarship.org/uc/item/77b7j33j>

### Journal

Scientific Reports, 15(1)

### ISSN

2045-2322

### Authors

Filipe, Alice

Saravi, Sayeh

Mustafov, Denis

et al.

### Publication Date

2025-07-01

### DOI

10.1038/s41598-025-05013-0

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



# OPEN Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer

Alice Filipe<sup>1</sup>, Sayeh Saravi<sup>1</sup>, Denis Mustafov<sup>1,2</sup>, Suzana Panfilov<sup>1</sup>, Simran Banger<sup>1</sup>, Seyedehnajmeh Mousavikivaj<sup>1</sup>, Maria Braoudaki<sup>2</sup>, Senthilkumar Kailasam<sup>3</sup>, Yasser Riazalhosseini<sup>3</sup>, Michelle A. Sahai<sup>1</sup>, Fotios Drenos<sup>1</sup>, Cristina Sisu<sup>1</sup> & Emmanouil Karteris<sup>1</sup>✉

Ovarian cancer (OvCa) is the sixth most common gynaecological cancer in the UK, accounting for over 200,000 deaths worldwide. Cancerous Inhibitor of Phosphatase 2 A (CIP2A) is an oncoprotein and an endogenous inhibitor of PP2A. CIP2A is a key regulator for cellular processes (e.g. proliferation, DNA damage) and is involved in the progression of many malignancies. In this study we provide a comprehensive overview of its role in OvCa making use of *in silico* tools, clinical samples and *in vitro* models. CIP2A is overexpressed in OvCa patients, with metastatic patients having significantly higher expression when compared to patients with malignant and benign ovarian tumours. High CIP2A expression reduces both overall and progression-free survival, whereas an R530T mutation is predicted to cause structural destabilisation of the CIP2A dimer. We also provide evidence for microRNA (miRNA) and mRNA target interactions with CIP2A. Finally, we have studied the effects of CIP2A inhibition in an *in vitro* BRCA2 model compared to BRCA2 wild-type OvCa cells, using RNA-sequencing. Gene enrichment pointed towards changes p53 pathway, protein metabolism, transporter activity, DNA replication, and cell cycle. Our data provide a novel insight into the role of CIP2A in OvCa and the potential of drug repurposing for therapeutic interventions.

Ovarian cancer (OvCa) is one of the leading causes of death for female patients with gynaecological cancers, responsible for 313,959 cases worldwide annually<sup>1</sup>. OvCa is an umbrella term for an amalgamation of different ovarian malignancies, each of which presents with distinct features, affecting disease progression<sup>2</sup>. Due to a lack of effective screening<sup>3</sup> as well as vague and confounding symptoms<sup>4</sup> approximately 70% of patients are diagnosed at the later stages (III or IV)<sup>3,4</sup>. Currently, no screening program for OvCa exists for the general population. This is because overall, the incidence of the disease is low and false positive screens for OvCa can result in unwanted interventions. Additionally, a screening test must detect OvCa in a state where it is treatable and potentially curable. Current strategies to diagnose OvCa are based primarily on blood tests (e.g. measuring CA-125, HE4) and imaging, both of which have certain limitations<sup>5,6</sup>.

The tumour suppressor, protein phosphatase 2 A (PP2A), is a serine/threonine phosphatase of vital importance for regulating many processes in the cell, such as cell growth, proliferation and apoptosis<sup>7</sup>. Cancerous inhibitor of PP2A (CIP2A) is a 90 kDa oncoprotein, encoded by the gene *KIAA1524* located at 3q13.13<sup>8,9</sup>. It functions as an endogenous PP2A inhibitor and plays a non-essential role in healthy physiology, since it has minimal expression in healthy tissues. Indeed, its highest expression has been documented in immune, intestinal and sperm cells<sup>9</sup>; contrary to its upregulation in certain cancers. These findings corroborate data from the Genotype-Tissue Expression (GTEx) portal, where very low expression of PP2A is measured in normal tissues including: adipose tissue, brain, breast, cervix, colon, fallopian tubes, heart, kidney, ovary, pancreas, prostate, stomach, uterus, vagina, and whole blood<sup>10</sup>.

Through inhibition of PP2A, CIP2A drives dysregulation of signalling pathways, since it can interact with other oncoproteins such as MYC, Akt, as well as mTOR to encourage tumour progression<sup>11</sup>. A number of studies have shown that CIP2A is over-expressed in many cancers including breast<sup>12</sup>, endometrial<sup>13</sup> and cervical<sup>14</sup>. In OvCa, CIP2A has been shown to be over-expressed in serous, endometrioid, mucinous, and clear cell carcinoma<sup>15</sup> with increased cytoplasmic CIP2A expression being associated with higher grade, more aggressive disease and

<sup>1</sup>Department of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of London, Uxbridge UB8 3PH, UK. <sup>2</sup>School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9JA, UK. <sup>3</sup>Victor Phillip Dahdaleh Institute of Genomic Medicine at McGill University, Montreal, QC H3A 0G4, Canada. ✉email: emmanouil.karteris@brunel.ac.uk

reduced overall survival (OS) and progression-free survival (PFS). Of note, *CIP2A* over-expression in OvCa, has been shown to correlate to chemotherapy resistance<sup>16</sup>.

In this study, we provide a deeper insight into the role of *CIP2A* in OvCa making use of in silico tools, RNA-sequencing, tissue microarrays and functional assays. More specifically, we studied the expression patterns of *CIP2A*, identified functional miRNA-mRNA target interactions (MTIs), modelled mutations involved in OvCa and studied its clinical utility as a biomarker. We have expanded on these observations, by mapping the protein distribution of *CIP2A* on a tissue microarray. Finally, we investigated the effect of *CIP2A* inhibition on the OvCa transcriptome in vitro, using TD-19, an Erlotinib derivative marketed as a *CIP2A* inhibitor.

## Results

### Expression of *CIP2A* (KIAA1524) in health and gynaecological malignancies

Data from the Genotype-Tissue Expression (GTEx) Project<sup>10</sup> demonstrate that *CIP2A* is co-expressed with *PP2A* in female organs under normal conditions, demonstrating a weak positive correlation (Supplementary Fig. 1a–c). Leveraging GTEx and the Cancer Genome Atlas (TCGA) data<sup>17</sup> we demonstrate that *CIP2A* is significantly upregulated in various gynaecological malignancies, including OvCa (Fig. 1a), irrespective of age of patients (Fig. 1b) or stage (Fig. 1c), whereas *CIP2A* was upregulated in Grade 3 (i.e. poorly differentiated, high grade) when compared to Grade 2 (Supplementary Fig. 1d). Consistently with results from *CIP2A* breast cancer studies<sup>18,19</sup> OvCa patients who carry a TP53 mutation, have significantly higher levels of *CIP2A*, when compared to TP53-non-mutants (Fig. 1d; UALCAN<sup>20</sup>). Using an OvCa single cell database, of 84 ovarian tumour patients –primarily high-grade serous carcinoma (HGSC)– from 16 publicly available studies<sup>21</sup> we demonstrate that *CIP2A* is expressed in a wide range of cells i.e., T/B/mast/myeloid/ epithelial/endothelial cells, pericytes and fibroblasts (Figs. 1e–g). Aberrant *CIP2A* expression in OvCa was further corroborated using information from the Spatial Transcript Omics DataBase (STOmics DB). There was no difference in the expression of *CIP2A* across the different clusters of a single patient with endometrial adenocarcinoma of the ovary. This is an ovarian primary tumour with no evidence of cancer spread to regional lymph nodes, or distant metastasis (T1N0M0; Figs. 1h–j)<sup>22</sup>.

### *CIP2A* is not frequently mutated in OvCa

The online tool cBioPortal<sup>23</sup> was used to determine gene alterations of *CIP2A* in 1880 OvCa patients. Only 4% of patients had alterations in the gene, which were either amplifications or missense mutations of unknown significance. On further investigation, three missense mutations were identified, R530T, E840K, and M628I, from three different patients, were associated with OvCa. Structural analysis of the *CIP2A* protein indicates that the residues E840 and M628I are located along the unstructured helical segment, whereas R530 is situated within a critical globular domain (Fig. 2a). The specific position of R530 is particularly noteworthy due to its potential role in dimerisation. A mutation at this site, such as R530T, is predicted to cause structural destabilisation owing to its integral role in maintaining the integrity of the globular domain (Fig. 2b). Consequently, the R530T mutation may directly disrupt dimerisation processes without impacting small molecule binding, given its considerable distance from other identified binding sites, as was described in a ligand binding study of lapatinib with *CIP2A*<sup>24</sup> (Fig. 2a). This underscores the mutation's potential effect on the structural and functional dynamics of *CIP2A*. In addition, using data from UK Biobank, no significant genetic associations were found between *CIP2A* and OvCa. The associations were primarily with reticulocyte and lymphocyte counts, as well as thyroid function (hypothyroidism; Supplementary Table 1).


### Protein expression of *CIP2A* in clinical samples

We have used a tissue microarray of 131 OvCa patients, to study the protein expression of *CIP2A* in clinical samples. Our results show that although age and stage (grouped as early vs. late) do not affect expression (Fig. 3a, b); metastatic OvCa patients have significantly higher expression of *CIP2A* when compared to malignant OvCa samples ( $p=0.0366$ ) and benign ovarian tumours ( $p=0.0326$ ; Fig. 3c). When we only compared HGS ( $n=75$ ) to LGS ( $n=18$ ), a significant increase of *CIP2A* in HGS was noted ( $p=0.0016$ ; Fig. 1d) Proteomic data (UALCAN), corroborate the *CIP2A* overexpression seen in our clinical cohort (UALCAN, data not shown). We have then investigated, using KM plot<sup>25</sup> the impact of *CIP2A* expression on overall survival (OS) and progression-free survival (PFS) in OvCa patients. Increased expression of *CIP2A* causes a significant decrease in OS ( $p=4.6e-05$ ,  $n=655$ , Fig. 3e) and PFS ( $p=5.1e-06$ ,  $n=614$ , Fig. 3f). These findings are fully in line with data published from Westermarck's lab<sup>16</sup>.


Following the KM plot results, we decided to determine the possible use of *CIP2A* as a biomarker through plotting a Receiver Operating Characteristics (ROC) curve and corresponding gene expression box-plots using ROC plot<sup>26</sup>. The plots represent 6-month relapse-free survival for both grade III stage III and grade III stage IV serous ovarian cancer (OvCa) patients who underwent platinum chemotherapy treatment. These datasets include data from 551 patients (505 responders and 46 non-responders) for grade III stage III and 88 patients (79 responders and 9 non-responders) for grade III stage IV. *CIP2A* (Fig. 3g and h) shows an area under curve (AUC) of 0.638 ( $p=0.018$ ) for grade III stage III and 0.75 ( $p=0.0013$ ) for grade III stage IV OvCa patients respectively.

### Protein expression of *CIP2A* is significantly increased in multiple pathways


We have expanded on these observations by employing in silico tools to further investigate protein expression of *CIP2A*, based on the mutation status of key signalling pathways involved in OvCa. These data are collated by the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC), and refer to pathway-level somatic alterations (by small mutation or copy number alteration) in OvCa with combined proteomic, whole-exome, and copy number alterations data. These include RTK (Supplementary Fig. 2a), NRF2 (Supplementary



**Fig. 1.** CIP2A (KIAA1524) is aberrantly expressed in ovarian cancer. CIP2A is significantly upregulated in breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), ovarian serous cystadenocarcinoma (OV), uterine corpus endometrial carcinoma (UCEC), and uterine carcinosarcoma (UCS), when compared to healthy controls (a). CIP2A expression is not dependent on patients' age (b), stages of OvCa (c), but is upregulated in OvCa patients that have TP53 mutations (d). Ovarian T/B/mast/myeloid/epithelial/endothelial cells, pericytes and fibroblasts express CIP2A (e-g). Spatial transcriptomics data on the expression of CIP2A across eight different clusters of a single patient with endometrial adenocarcinoma of the ovary (h-j).



**Fig. 2.** (a) Structure of the wild-type CIP2A protein as predicted by AlphaFold2 (Identifier: AF-Q8TCG1-F1) (purple). The three potential sites for the E840K, M628I, and R530T mutations are highlighted in blue spheres. The zoomed-in image shows the location of one of the mutation sites, R530 with respect to the four previously predicted ligand binding sites. (b) 3D structure of the apo-CIP2A dimer (PDB ID: 5UFL), revealing the dimerisation interface involving the residues L529, V525, L532, L533, L546, L550 (green) and R530 (yellow) between chain A (blue) and chain B (purple). The structures were processed and images generated using the VMD (Visual Molecular Dynamics) software.



**Fig. 3.** Protein expression of CIP2A depending on the patient's age (a), FIGO stage (b), malignant, metastatic and benign status (c), and pathological diagnosis: HGS (high-grade serous), LGS (low-grade serous), CCC (clear cell carcinoma), MUC (mucinous), EAC (endometrioid adenocarcinoma), KT (Krukenburg tumour), and LN (lymph node) (d). The images of the cores presented within the figure are representative of the group and were captured at 10x magnification. Overexpression of CIP2A is associated with poorer OS (e) and PFS (f). Six-month relapse-free survival for (g) stage III serous ovarian cancer (OvCa) patients who underwent platinum chemotherapy treatment (total  $n = 551$ , responders  $n = 505$ , and non-responders  $n = 46$ ) and (h) stage IV serous OvCa patients who underwent platinum chemotherapy treatment (total  $n = 88$ , responders  $n = 79$ , and non-responders  $n = 9$ ;  $p = 0.018$  and  $p = 0.0013$ , respectively).




Fig. 2b), WNT (Supplementary Fig. 2c), SWI-SNF Supplementary (Supplementary Fig. 2d), MYC/MYCIN (Supplementary Fig. 2e), p53Rb-related (Supplementary Fig. 2f), HIPPO (Supplementary Fig. 2g), mTOR (Supplementary Fig. 2h) and chromatin modifier status (Supplementary Fig. 2i). Protein expression of CIP2A is significantly increased in all tested mutated pathways when compared to normal samples. In addition, p53Rb-related and mTOR pathway mutations demonstrate a significant increase in CIP2A expression when compared to non-mutated pathways with p-values of 0.0297 and 0.0426, respectively.

### Identification of miRNA: mRNA interactions and investigation into their impact

To identify miRNA: mRNA interactions, an investigation of four predictive databases was undertaken (supplementary Fig. 3). These were miRDB, TargetScan, miRSystem, and ENCORI, which identified 95, 623, 37, and 51 interactions respectively (Fig. 4). The results showed that there were two common miRNAs (miR-576-5p and miR-577) across all four databases (0.3%) that were targeting *KIAA1524*.

Following on, we evaluated their strength of binding to *CIP2A* through Sfold binding analysis. Primarily, the interaction between miR-576-5p and *CIP2A* was investigated. This analysis showed that there is only one binding site between miR-576-5p (red) and *CIP2A* (black) at the 3'UTR (untranslated region) at position 3017–3033 with a  $\Delta G_{\text{hybrid}}$  of -12.4 (Fig. 4b, Table 1). As well as this, the seed type identified was 8mer, signifying that the miRNA potentially binds to *CIP2A* with full complementarity and could lead to its complete degradation. Sfold analysis was also used to examine the interactions between miR-577 and *CIP2A*. The results showed three binding sites between miR-577 and *CIP2A*. The most substantial primary interaction, at the 3'UTR at position 2826–2841, with a  $\Delta G_{\text{hybrid}}$  of -13.5, and a seed type 8mer. The second interaction is at the 3' UTR at position 2881–2904, with a  $\Delta G_{\text{hybrid}}$  of -13.1, and a seed type 7mer-A1. The third interaction is at the 3'UTR at position



**Fig. 4.** miRNA: *CIP2A* interactions. (a): A Venn diagram representing the results from a bioinformatics analysis based on four predictive miRNA-mRNA databases (miRDB, TargetScan, miRSystem, ENCORI), (b): Sfold analysis displaying the interaction between miR-576-5p (red) and *CIP2A* (black). Evidence of binding at the 3'UTR at position 3017–3033 with a  $\Delta G_{\text{hybrid}}$  of -12.4 and an 8mer seed type, (c-e): Interactions between miR-577 (red) and *CIP2A* (black). Three binding sites between miR-577 (red) and *CIP2A* (black) were identified via the Sfold analysis at the 3'UTR at positions 2826–2841, 2881–2904, and 2826–2839, with a  $\Delta G_{\text{hybrid}}$  of -13.5, -13.1, and -9.7 respectively. These also show a seed type of 8mer, 7mer-A1, and offset-6mer respectively, (f): Sfold analysis displaying the interaction between miR-383-5p (red) and *CIP2A* (black). One binding site was identified at the 3'UTR at position 2893–2925, with a  $\Delta G_{\text{hybrid}}$  of -20 and a seed type of 6mer, (g): Sfold analysis displaying the interaction between miR-224-5p (red) and *CIP2A* (black). One binding site identified at the 3'UTR at position 2859–2879, with a  $\Delta G_{\text{hybrid}}$  of -20.1 and a seed type of 7mer-m8, (h): String analysis depicted ten proteins interacting with *CIP2A*. These proteins were encoded by the genes: *MYC*, *E2F1*, *BRCA1*, *PLK1*, *MINK1*, *PPME1*, *PPP2R1A*, *SET*, *SMC2*, and *KIF11*, and (i): miRNA bundles depicted by miRNet bioinformatics analysis regulating the genes interacting with *CIP2A*. Please note none of the miRNAs regulating/interacting with the ten genes was depicted during miRNA: mRNA interaction analysis performed by miRDB, TargetScan, miRSystem, ENCORI, and Sfold (yellow circles - genes; blue/green circles - miRNAs).

| miRNA          | Site Position | LegitProb $\left[ \frac{+}{-} \right]$ | Score | Seed Positions | Seed Type   | 3'bp* | $\Delta G_{\text{hybrid}}$ |
|----------------|---------------|----------------------------------------|-------|----------------|-------------|-------|----------------------------|
| hsa-miR-576-5p | 3017-3033     | 0.744                                  | 0.167 | 3027-3033      | 8mer        | 0     | -12.4                      |
| hsa-miR-577    | 2826-2841     | 0.863                                  | 0.095 | 2834-2840      | 8mer        | 0     | -13.5                      |
| hsa-miR-577    | 2881-2904     | 0.69                                   | 0.095 | 2898-2903      | 7mer-A1     | 0     | -13/1                      |
| hsa-miR-577    | 2826-2839     | 0.619                                  | 0.095 | 2834-2839      | offset-6mer | 0     | -9.7                       |
| hsa-miR-383-5p | 2893-2925     | 0.616                                  | 0.421 | 2919-2924      | 6mer        | 0     | -20                        |
| hsa-miR-224-5p | 2859-2879     | 0.673                                  | 0.249 | 2873-2879      | 7mer-m8     | 0     | -20.1                      |

**Table 1.** Sfold binding analysis between miR-576-5p, miR577, mR-383-5p, mir-224-5p and *CIP2A*.

| miRNA conserved sites | Position in the UTR | Seed match | Context ++ score | Context ++ score percentile | Weighted context ++ score | Conserved branch length | Pcr  |
|-----------------------|---------------------|------------|------------------|-----------------------------|---------------------------|-------------------------|------|
| hsa-miR-383-5p.2      | 133–139             | 7mer-m8    | -0.16            | 89                          | -0.15                     | 2.899                   | <0.1 |
| hsa-miR-224-5p        | 2524-2531           | 8mer       | -0.16            | 92                          | -0.01                     | 2.165                   | N/A  |

**Table 2.** TargetScan conserved mirna: mRNA binding interaction analysis depicted two MiRNAs targeting *CIP2A* with great affinity: miR-383-5p and miR-224-5p, respectively.


2826–2839, with a  $\Delta G_{\text{hybrid}}$  of -9.7, and a seed the offset-6mer (Fig. 4c-e; Table 1). The presence of multiple binding sites between miR-577 and *CIP2A* suggested a greater modulation of gene expression by this miRNA.

TargetScan identified two additional miRNAs targeting *CIP2A* with great affinity: miR-383-5p and miR-224-5p (Table 2). These were further investigated with Sfold. The analysis highlighted one binding site between miR-383-5p (red) and *CIP2A* (black) at the 3'UTR at position 2893–2925, with a  $\Delta G_{\text{hybrid}}$  of -20 and a seed type of 6mer. The study of the interaction between miR-224-5p (red) and *CIP2A* (black) showed that the binding occurs at the 3' UTR at position 2859–2879, with a  $\Delta G_{\text{hybrid}}$  of -20.1 and a seed type of 7mer-m8 (Fig. 1f-g). The protein interactome analysis of *CIP2A* demonstrated its interaction with 10 proteins, encoded by the following genes: *MYC*, *E2F1*, *BRCA1*, *PLK1*, *MINK1*, *PPME1*, *PPP2R1A*, *SET*, *SMC2*, and *KIF11* (Fig. 4h-I, and Supplementary Table 2).

Using the database of Differentially Expressed MiRNAs in human Cancers (dbDEMC)<sup>27</sup> and making use of publicly available patient-derived datasets, we demonstrate that miR-576-5p and miR-383-5p are downregulated in OvCa (logFC: -2.68 and -7.36 respectively; datasets GSE65819 and GSE119055). miR-577 demonstrated a weak increase (logFC: 0.68; dataset GSE106817) and miR-224-5p appears to be upregulated in OvCa (logFC: 5.30; dataset GSE83693).

### Inhibition of *CIP2A* using TD-19

We used the TD-19, an Erlotinib derivative marketed as a transcriptional *CIP2A* inhibitor, to gain a better insight into the role of *CIP2A* in an in vitro BRCA2 model (PEO1) compared to BRCA2 wild-type (PEO4). RNA sequencing revealed that TD-19 induced cell-specific differential expression for 50 genes in PEO1 cells, and 4058 in PEO4, as well as pointing at 342 DEGs in both systems (Fig. 5a, Supplementary Tables 3 and 4). A t-distributed stochastic embedding (t-SNE) plot based on the DEG data demonstrated a robust discrimination, both between PEO1 and PEO4 samples and between TD-19 treated and control samples (Supplementary Fig. 4a). TD-19 treatment (5  $\mu$ M for 24 h), downregulated *CIP2A* primarily in the BRCA2 wild type (wt) cell line, PEO4 (Supplementary Fig. 4b-d). A Uniform Manifold Approximation and Projection (UMAP) plot was created to display the up- (red) and down-regulated (blue) genes for PEO1 and PEO4 samples (Fig. 5b) and TD-19 5  $\mu$ M treated and control samples (Fig. 5c). The results show a complete contrast between the two cell lines as well as between treated (both cell lines combined) and control samples (i.e. untreated).



**Fig. 5.** Differentially expressed genes and enriched biological pathways, processes and molecular functions associated with TD-19 treatment in PEO1 and PEO4 cells. **a**) A Venn diagram displaying the differentially expressed genes (DEGs) for TD-19 treated PEO1 and PEO4 samples when compared to their respective controls, **(b–c)** Geneset signature uniform manifold approximation and projection displaying up and down-regulated genes in different samples. UMAPs display genes clustered by relative log-expression which were up (red) or down (blue) regulated in PEO1 and PEO4 **(b)**, no supplement (control) and treated samples **(c)**. Images produced using Omics Playground. Top 5 enriched **(d)** and **(g)** Biological Pathways, **(e)** and **(h)** Biological Processes, and **(f)** and **(i)** Molecular Pathways for PEO1 and PEO4 cell lines respectively, treated with TD-19.

### Gene enrichment analysis

Funrich was used to determine the top five enriched biological pathways (Fig. 5d), biological processes (Fig. 5e), and molecular pathways (Fig. 5f) in PEO1 cells treated with TD-19. The results show involvement in p53 pathway, protein metabolism, and transporter activity. Interestingly, the rest of the biological pathways are related to kinase activity, two of which are known to be important in cancer (ErbB and ERK). To further corroborate this under molecular pathways protein tyrosine/serine/threonine kinases were also highlighted. For biological processes, cell-cell adhesion was one of the five which is important and could indicate a relationship with EMT and thus metastasis. Similar analyses were performed for the PEO4-related DEGs, identifying the top five enriched biological pathways (Fig. 5g), biological processes (Fig. 5h), and molecular pathways (Fig. 5i). Of note, all of the biological pathway data show involvement in DNA replication, and the cell cycle. Regulation of nucleobase, nucleoside, nucleotide, and nucleic acid metabolism are also part of the top five biological processes. For molecular pathways, the top two were catalytic and GTPase activity. All p-values for the top five enriched biological pathways, biological processes, and molecular pathways (depicted in Fig. 5) were significant (Supplementary Fig. 5a–b).


### Heat map of the top 150 DEGs identifies four different clusters

Figure 6a depicts the functional heat map of the top 150 genes identified based on differential expression pattern with the highest standard deviation across all samples ([PEO1 vs. PEO4 and treatment] vs. control). The hierarchical clustering was performed at the gene level and showcased four clusters S1–S4 (Fig. 6b). Many of these functional annotations are related to cancerous pathways such as the TNF- $\alpha$  signalling via NF- $\kappa$ B, MYC targets, and p53 pathway in S1, Oestrogen response early, E2F targets, and G2M checkpoint in S2, Interferon alpha and gamma response in S3 (TNF- $\alpha$  signalling via NF- $\kappa$ B also appears in this cluster), and mTOR signalling, PI3K-Akt-mTOR signalling and MYC targets in S4.

### TD-19 treatment acts similarly to other drug treatments

Omics Playground allows for the determination of correlation between dysregulated genes as a result of TD-19 treatment and as a result of other known drug profiles from the L1000 database<sup>28</sup>. In essence, this analysis identifies which drugs can give a similar genetic signature to TD-19. Figure 6c shows the results for this with 16 top drug profiles shown, with the closest profile to TD-19 being Homoharringtonine, an anti-cancer drug already





**Fig. 6.** Clustered heatmap and functional annotation. **a**) Functional heat map of 150 genes identified through the highest standard deviation across all samples (PEO1 vs. PEO4 and treatment vs. control). The hierarchical clustering was performed at the gene level and using the relative expression scale. In this heatmap, red signifies over-expression and blue under-expression. There are four clusters S1 (blue), S2 (orange), S3 (green), and S4 (red). **b**) The functional annotation terms for each of the four clusters identified in (a). These were generated through the use of Omics Playground which correlates each gene set to over 42 reference databases such as KEGG and Gene Ontology. **c**) Drug connectivity and mechanisms of action. **d**) The correlation between the TD-19 treatment data and known drug profiles from the L1000 database. Here, each of the drugs from the databases shows a similar gene dysregulation pattern observed with TD-19 treatment. Each of the bars represents a gene; red signified up-regulation and blue down-regulation. **d**) A plot displaying the most correlated mechanisms of action (MOA) across the enriched drug profiles identified from the L1000 activities database compared to TD-19. The Gene Set Enrichment Analysis (GSEA) normalised enrichment score is on the y-axis and the MOA is on the x-axis.

in clinical use. Some other compounds of interest were the mTOR inhibitor (Torin-2) and another clinically used anti-cancer drug Bortezomib. Following on from this, the most correlated mechanisms of action (MOA) across the enriched drug profiles identified from the L1000 activities database compared to TD-19 were determined and are shown in Fig. 6d. We selected the positively correlated MOA of interest as: NFκB pathway inhibitor, mTOR inhibitor, and protein synthesis inhibitor, and the negative are RNA polymerase inhibitor, TGFβ receptor inhibitor, EGFR inhibitor, oestrogen receptor agonist, and p38 MAPK inhibitor.

We have also interrogated the correlation of expression patterns between *KIAA1524* and other genes, using Omics Playground<sup>29</sup> and the results are shown in Supplementary Fig. 6. Both conditions tested (i.e. PEO1 and PEO4), show strong positive correlations with *CIP2A* and *EPCAM*, *POLB*, *MFS8D8*, and *OSTF1*.

### Effects of TD-19 on cell proliferation

In order to investigate the effects of TD-19 on cell proliferation, we have used the ovarian carcinoma cell line SKOV-3 as a preclinical model. We have decided to use this cell line as it is one of the most frequently used OvCa in vitro models (both 2D and 3D)<sup>30</sup>. Moreover, when we performed RT-qPCR, we demonstrated that SKOV-3 cells express higher amounts of *CIP2A* when compared to PEO1 ( $p < 0.0001$ ) or PEO4 ( $p = 0.0075$ ) cell lines (data not shown); thus, making it an ideal target for TD-19. A wound healing assay was initially used to explore the migratory and proliferative capacity of TD-19 treated SKOV-3 cells over 72 h (5μM). The gap closure was delayed in the treated cells when compared to control cells (no treatment; Supplementary Fig. 7a-b). This was corroborated by a cell viability assay, demonstrating that SKOV-3 cells treated with TD-19 demonstrated a significant decrease ( $p < 0.001$ ) in numbers of live cells over 24–72 h (Supplementary Fig. 7c). Furthermore, there was an increase in the apoptotic population (early apoptosis; annexin V+/PI-, late apoptosis; annexin V+/PI+) in treated cells over 24–72 h (Supplementary Fig. 7d).

## Discussion

In this study we provide a comprehensive overview of the role of CIP2A in OvCa. Our data corroborate previous studies that demonstrated overexpression in 39–90% of malignancies, including OvCa<sup>11,15</sup>. *CIP2A* upregulation in OvCa was independent of stage or age, but significantly overexpressed in OvCa patients that have TP53 mutations. Indeed, previous studies have shown that *CIP2A* expression is stimulated by TP53 mutation in head and neck cancer<sup>31</sup> and its inactivation (via the P21-E2F1 axis) modulates *CIP2A* expression<sup>9,19</sup>. We also show an increased expression of *CIP2A* in patients who have mutations in their mTOR-pathways when compared to when compared to non-mutated pathways patients and healthy controls. *CIP2A* is known to affect mTOR complex 1 (mTORC1) signalling which not only inhibits autophagy but also increases cell growth and proliferation<sup>11</sup>. Puustinen et al., have also linked *CIP2A* with mTOR activity, since it promotes mTORC1-mediated cell proliferation and inhibition of autophagy<sup>32</sup>.

Using tissue microarrays, we demonstrate aberrant expression of *CIP2A* in OvCa patients, independent of age or stage (early vs. late). Emerging spatial transcriptomics data corroborates similar expression. We also provide evidence for overexpression of *CIP2A* in metastatic patients when compared to primary tumour samples indicating its potential involvement as an oncoprotein in the progression of the disease. This finding agrees with the study by Böckelman et al.<sup>33</sup>, where they demonstrate that increased *CIP2A* expression is associated with more aggressive OvCa and worsen survival. The KM plots presented here corroborate this further, since increased expression of *CIP2A* in OvCa patients, both serous and endometrial, was associated with significantly poorer OS and PFS. Further verification comes from investigations into many other solid tumours, which indicate that increased expression of *CIP2A* is associated with poorer outcomes<sup>8</sup>. We have also shown that mucinous OvCa has a high *CIP2A* expression. Of note, there is a high percentage of patients with TP53 mutations, suggestive of potential involvement in the upregulation of *CIP2A* in mucinous OvCa<sup>34</sup>.

Little is known about the impact of *CIP2A* mutations in health and disease. For example, the activating *CIP2A* p.D269V mutation, is a novel genetic cause for this malignancy, as it drives increased expression of PP2A, mTOR, and c-Myc<sup>35</sup>. Loss of function variant in *CIP2A* (c.1510 C>T, p.L504F), has also been identified as a cause for early embryonic arrest and fragmentation, from a consanguineous family<sup>36</sup>. UK Biobank analysis did not reveal any associations of polymorphisms with OvCa. It appears therefore, that the protein is so widely over expressed in cancer by so many oncogenic pathways that there is no need for mutations, and overexpression is enough as an oncogenic driver. However, in this study we identify that the R530T mutation presented in an OvCa patient, can potentially cause structural changes affecting the dimerisation of this molecule. To further elucidate the impact of the R530T mutation and other mutations on the *CIP2A* structure and function, several advanced computational studies could be undertaken in future studies. Future molecular dynamics (MD) simulations could be employed to observe the dynamic behaviour of both the wild-type and mutant *CIP2A* proteins, providing insights into conformational changes, stability, and interactions over time. This could enhance our understanding of *CIP2A*'s structural and functional dynamics and guide experimental validation studies. Despite the lack of direct association between *CIP2A* and OvCa, based on UK Biobank data, it is worth mentioning that other associations provide a novel insight into the role of this gene. For example, a genome-wide association study (GWAS) for certain endocrine indices, found a causal relationship between OvCa and thyroid function<sup>37</sup> whereas late stage OvCa patients were found to have significantly lower reticulocyte counts when compared to healthy controls<sup>38</sup>.

Our miRNA: mRNA in silico analysis showed that *CIP2A* was a direct target for miR-576-5p and miR-577. A recent study observed that a circular RNA called hcR1445 reduced cellular invasion, proliferation, and migration by inhibiting miR-576-5p, suggesting the overexpression of miR-576-5p in OvCa and its action as an oncomiR<sup>39</sup>. The role miR-576-5p has also been related to the upregulation of *SFRP1* expression, which in turn activates WNT/ $\beta$ -catenin signalling, promoting OvCa progression<sup>39</sup>. Our Sfold analysis depicted one binding site between miR-576-5p and *CIP2A*, hinting at a potential regulatory function for the miRNA. In miRNA-mediated upregulation, microRNA ribonucleoproteins (miRNPs) can act in trans to enhance the expression of their target mRNAs. This upregulation can occur through the direct action of miRNPs on the mRNA or by indirectly relieving the mRNA from repression by inhibiting the activity of repressive miRNPs<sup>40</sup>. Thus, we could hypothesise that miR-576-5p has protective mechanisms upon *CIP2A*, preventing post-translational repression or degradation. Nevertheless, the expression of miR-576-5p in OvCa has not been deeply studied and further research is necessitated to identify its exact molecular mechanisms and mode of action.

On the other hand, our four-database miRNA: mRNA interactome analysis showed that *CIP2A* was also targeted by miR-577. Previous research has demonstrated that the expression of miR-577 in OvCa cells was significantly downregulated<sup>41</sup>. Additionally, miR-577 was identified as a direct downstream target for a long intergenic non-coding, *LINC01094*. Inhibition of miR-577 led to the expression of *LINC01094* and enhanced its proliferative effects upon OvCa cells, suggesting the tumour-suppressive properties of miR-577 in OvCa<sup>41</sup>. Our analysis also depicted three binding sites between miR-577 and *CIP2A*, suggesting a robust and efficient regulation of the mRNA, ensuring precise control over gene expression by promoting mRNA degradation and inhibiting tumour growth.

Furthermore, we identified that miR-383 was also targeting *CIP2A*. This interaction has been previously demonstrated in glioma cells, where miR-383 inhibited the expression of *CIP2A* and seized the proliferation and invasion of the cancer cells<sup>42</sup>. The significant downregulation of miR-383 in OvCa has also been observed<sup>43</sup>. Even though the interaction between miR-383 and *CIP2A* has not been previously reported in OvCa, we could suggest that miR-383 could exert its tumour suppressive properties via targeting the genes, consequently leading to tumour growth inhibition. In contrast, the upregulated expression of miR-224-5p in OvCa has been observed<sup>44</sup>. Nevertheless, its interactions with *CIP2A* have not been elucidated before. Based on the data generated from dbDEMC, the observed downregulation of miR-576-5p and miR-383-5p supports our hypothesis that loss of these two miRNAs might relieve suppression on *CIP2A*, leading to its upregulation. Considering that these

findings are derived from clinical samples, this data strengthens the idea of a regulatory axis between these two miRNAs and *CIP2A* in a biologically relevant context.

Inhibition of *CIP2A* with TD-19 in BRCA2 mutant and wild-type preclinical OvCa models, provided a novel insight into transcriptomic changes. We have chosen these in vitro models, since it has been shown that in cells that are BRCA deficient, the *CIP2A* forms a complex with TOPBP1 that subsequently prevents lethal mis-segregation of chromosomes (lacking centromeres), due to impaired DNA synthesis<sup>45</sup>. TD-19, an Erlotinib derivative, is marketed as a *CIP2A* inhibitor. TD-19 differs from Erlotinib as 4-phenoxyaniline is added at position 2 of quinazoline. This prevents TD-19 from binding via hydrogen bond to EGFR ATP-binding site as Erlotinib does<sup>46</sup>. TD-19 has been shown to be effective at inducing apoptosis in non-small cell lung cancer (NSCLC) cell lines at a concentration of 5–10  $\mu$ M<sup>46</sup> and in mouse testicular cells, *CIP2A* was significantly down-regulated after treatment with TD-19<sup>47</sup>. Similarly, we also demonstrate a decrease of cell proliferation in vitro, following TD-19 treatment.

Functional enrichment in Gene Ontology terms, was performed in relation to the top 5 biological pathways, biological processes, and molecular pathways for both cell lines, treated with TD-19. In terms of biological pathways (PEO1, BRCA2 mutant), p53 pathway was highly enriched. Although there is some evidence of an interaction between *CIP2A* and p53, the whole mechanism is not fully elucidated yet. This is not a surprise, given the links between TP53 and *CIP2A*. TP53 is mutated in over 96% of cases in high-grade serous OvCa<sup>48</sup>. We also provide evidence for potential interactions with ErbB receptor and ATR signalling pathway. Of note, overexpression or activation of ErbB receptors, has been linked with poor prognosis and metastatic events<sup>49</sup>. ATR signalling tends to get activated when the genome responds to single-stranded DNA gaps, and in OvCa, interruption of ATR signalling further sensitised BRCA1/2-deficient OvCa cells to PARP inhibition<sup>50</sup>. In terms of biological processes, the most enriched pathway was that of protein metabolism. Indeed, in OvCa, metabolic alterations are key in order for cancer cells to sustain uncontrolled proliferation, and rebuild biomasses including proteins<sup>51</sup>. In the BRCA2 wild-type PEO4 cells, the top five enriched biological pathways were all shown to be involved in the regulation of the cell cycle. *CIP2A* has been shown to be involved in promoting cell cycle progression in triple-negative breast cancer (TNBC) cells, whereas its inhibition, leads to cell cycle arrest in hepatocellular carcinoma cells<sup>52</sup>. As mentioned previously *CIP2A* is also involved in the cell cycle progression through interactions with for example Plk1 or E2F1<sup>9,53</sup>. An analogous enrichment pattern to PEO1 cells was also noted, in terms of biological processes, with metabolism and energy pathways being the predominant ones. Heat map of the top 150 DEGs, identified similar clusters to the enriched pathways, including PI3K-Akt-mTOR signalling and MYC targets. Finally, a strong correlation was identified with *CIP2A* and EpCAM, a transmembrane glycoprotein that is over-expressed in many cancers including ovarian, breast, and lung<sup>54</sup>. It is a cell adhesion molecule, playing an important role in EMT and metastasis<sup>55</sup>. This provides a further link to the biological processes data for PEO1 in terms of cell-cell adhesion.

The drug screening provided a wide repertoire of compounds which act similarly to TD-19 displaying a comparable molecular signature. These results show that many small molecule inhibitors of proteases (MG-132, MLN-2238) and *CIP2A* interacting proteins such as mTOR inhibitors (Torin-2) were identified, which have been studied for their possible use for cancer treatment, yielding positive results in vivo<sup>56</sup>. Perhaps more interestingly, two of the identified drugs are clinically used drugs. For example, Homoharringtonine is used for chronic myeloid leukaemia and has been shown to suppress growth and induce apoptosis in TNBC<sup>57</sup> NSCLC<sup>58</sup> and hepatocellular carcinoma<sup>59</sup>. Bortezomib is also used for treating multiple myeloma patients and works as a proteasome inhibitor<sup>60</sup>. Collectively these data point towards potential drug repurposing. Future studies should concentrate on elucidating whether any of the compounds described in this study can exert an inhibitory effect on *CIP2A* signalling. Moreover, a recent study by Avelar et al., has shown that using a small-molecule activator of PP2A termed SMAP-061, appears to potentiates DNA damage-induced cell death in patient-derived HGSC cells and xenograft models alone or in combination with PARP inhibitors<sup>61</sup>.

## Conclusion

This study provided a deeper insight into the role of *CIP2A* in ovarian cancer making use of a wide repertoire of approaches. We provide further evidence of the regulation of signalling mechanisms using a *CIP2A* inhibitor, and identified compounds that can exert similar effects. We also acknowledge that our study has certain limitations. For example, given that HGSC is characterised by p53 mutations and accounts for the majority of high-grade ovarian tumours, it would be of interest to identify which cohorts of patients carry a p53 mutation and subsequently have a higher expression of *CIP2A*. Moreover, we have used a small cohort of patients for this study, and have not validated the impact of TD-19 on certain signalling pathways in vitro. Future studies should concentrate on increasing the TD-19 testing on different preclinical models of OvCa (e.g. endometrioid, early stage, etc.), and then move to in vivo studies, such as using models of subcutaneous tumorigenesis in nude mice. Given the increasing clinical utility of liquid biopsies, it will also be useful to study the expression of *CIP2A* in circulating tumour cells, and its gene expression in total RNA (from whole blood) as well as circulating-free RNA.

## Methodology

### In silico *CIP2A* (KIAA1524) analyses

The GTEx Portal<sup>10</sup> was used to identify the variation in *CIP2A* expression in normal breast and gynaecological tissues. The online tool OncoDB<sup>17</sup> was used to investigate *CIP2A* expression in OvCa in comparison to normal healthy tissues. As well as this, the online tool UALCAN<sup>20</sup> was used to allow for analysis of *KIAA1524* gene and *CIP2A* protein expression in cancers. CbioPortal<sup>23</sup> was used to determine common mutations on the *CIP2A* gene and determine the location of these mutations. AlphaFold2<sup>62</sup> was used to predict the protein structure

of CIP2A and to determine per-residue confidence scores (PLDDT) of specific locations on the protein. The protein structures for CIP2A were processed and images generated using the VMD (Visual Molecular Dynamics) software<sup>63</sup>.

The tool KM plot<sup>64</sup> was used to determine the impact of the expression of genes of interest on overall survival (OS) and progression-free survival (PFS) in OvCa. The tool ROC Plotter<sup>26</sup> was used to generate ROC plots to determine the predictive value of CIP2A as a biomarker in OvCa. For the genotyping study, UK Biobank (a large population database of around half a million individuals) was used as previously described<sup>65,66</sup>.

### In silico miRNA analysis

The following analysis was performed as previously described by Mustafiov et al., 2024<sup>67</sup>. In brief the databases, miRDB<sup>68</sup> TargetScan<sup>69</sup> miRSystem<sup>70</sup> and ENCORI<sup>71</sup> were employed to identify functional miRNA: mRNA target interactions (MTIs). Following this, the results from the four databases were plotted in a Venn diagram using Venny2.1.0<sup>72</sup> to identify the more efficacious MTIs and eliminate the chance of false positive results. The database miRbase<sup>73</sup> was used to obtain miRNA sequences and annotations. Following this, the database Sfold<sup>74</sup> was utilised to determine the probable binding sites of the identified miRNAs to their gene target. The database STRING<sup>75</sup> was used to identify the top co-expressed genes with CIP2A and these were used to plot a network of MTIs with CIP2A and its co-expressed genes using miRNET2.0<sup>76</sup>.

### Cell culture

PEO1 and PEO4 cell lines were used to model OvCa in vitro. These two cell lines were specifically chosen as they originate from the peritoneal ascites of the same patient who presented with poorly differentiated serous adenocarcinoma. Primarily, the patient had a BRCA2 mutation ((5193 C>G (Y1655X) (PEO1) and went on to relapse and present with a novel mutation which caused restoration of BRCA2 (5193 C>T (Y1655Y)) (PEO4). Both cell lines were cultured in Roswell Park Memorial Institute (RPMI) medium 1640 and GlutaMAX (61870-010, Gibco) supplemented with 10% foetal bovine serum (FBS) (10270-106, Gibco) and 1% penicillin-streptomycin (p/s) (15070-063, Gibco). Cells were incubated at 37 °C with 5% Carbon Dioxide (CO<sub>2</sub>) and passaged around two to three times a week when approaching 80% confluence using TrypLE™ Express Enzyme (12604013, Gibco). For functional experiments, the SKOV-3 cell line (ECAAC 91091004) was grown in Dulbecco's modified Eagle's medium (DMEM), as previously described<sup>77</sup>.

### TD-19 treatment

The inhibitor TD-19 (5329120001, Sigma-Aldrich) was dissolved in DMSO, aliquoted and stored at -20 °C. PEO1 and PEO4 cells were seeded at 80% confluence and left until a confluent monolayer formed (around 1 day) with 2mL of media. Once confluent, the media was replaced with 2mL of fresh pre-warmed media and treated with 5µM of TD-19. The no-supplement cells were treated with the same amount of DMSO. The 6-well plates were then placed in the incubator at 37 °C with 5% CO<sub>2</sub>. After 24 h of treatment, protein extraction for western blots and RNA extraction were performed.

### RNA extraction, sequencing, and analysis

Following TD-19 treatment, RNA extraction on PEO1 and PEO4 cells was performed using the RNeasy® Mini Kit (74104, Qiagen) following the manufacturer's instructions. The isolated RNA was sent on dry ice for sequencing by Novogene, Cambridge, for pair-end sequencing. The Tuxedo Suite software package was used to analyse the RNA-seq results. Pair-end reads were mapped to the human reference genome (GRCh38) using Tophat2 (v.2.1.1) and Bowtie2 (v.2.2.6). Following this, Samtools (v.0.1.19) was used to merge the replicates and filter the aligned reads to a quality threshold of < 30. To assemble and quantify the transcript, GENCODE annotation v26, Cufflinks (v.2.2.1), and Cuffdiff (v.2.2.1) were used to determine the differentially expressed genes (DEGs) of the treated samples compared to the control samples. The online tool FunRich<sup>78</sup> was used to analyse the involvement of the DEGs as a result of TD-19 treatment in biological processes, molecular functions, and biological pathways. As well as this, the online tool<sup>29</sup> was used to input the RNA sequencing data to perform various analyses and generate graphs.

### Western blotting

The Western blotting was performed as previously described<sup>77</sup>. In brief, protein lysate extraction was performed using pre-boiled Laemmli buffer (S3401-1VL, Sigma), followed by boiling the samples for 10 min at 100 °C. The gel was cast, samples and ladder loaded, and the electrophoresis was performed at 80 mA constant and 300 V for 50 min. Following this, the wet transfer was performed at 400 mA and 300 V for 90 min. The blocking stage was then performed for 1 h at RT. After this, the primary antibodies were prepared, CIP2A (1:500, Ab84547, Abcam) and GAPDH (1:1000, 2118 S, Cell Signalling) diluted in 5% BSA/TBS-Tween 20 overnight at 4 °C. The following day, the membrane was washed in TBS-Tween 20 three times. The secondary HRP antibody goat anti-rabbit (1:2000, ab205718, Abcam) was diluted in 1:2000 in 5% BSA/TBS-Tween 20 for 1 h on the rocker at RT followed by three washes in TBS-Tween 20. To visualise the bands, the chemiluminescent substrate was made and added to the membrane for two minutes in a dark room. After this, the membrane was transferred to the cassette with an Amersham™ Hyperfilm™ ECL™ (28-9068-36, Cytiva) photo paper placed onto it. The cassette was then closed for one minute then the film placed in the AGFA Curix 60 film developer. The blots were then analysed using densitometric analysis on the software ImageJ. Statistical analysis was conducted using a t-test, where \**p* < 0.05.

### Immunohistochemistry (IHC)

IHC was performed as previously in Filipe et al., 2021<sup>79</sup>. In brief, commercially available, paraffin-embedded tissue microarray slides containing OvCa patient samples and normal adjacent ovarian tissue (NAT) samples



were purchased (BC11115d and OV991, US Biomax Inc., Derwood, MD 20855, USA) (Supplementary Tables 5 and 6 respectively). These tissue samples were collected with full consent from the patients, in compliance with Health Insurance Portability and Accountability Act (HIPAA) approved protocols to ensure ethical standards. Use of commercially-available TMAs falls under the HTA licence of Brunel University London (#12543). The slides underwent de-paraffinisation through a series of washes, primarily in Histo-Clear (12358637, National Diagnostics, Loughborough, LE11 5RG, UK), 50:50 Histo-Clear and ethanol, then a serial dilution of ethanol. The antigen retrieval step was performed in heated sodium citrate (BP1325-1, Fisher Bioreagents, Loughborough, LE11 5RG, UK) for 10 min, followed by a series of washes in distilled water and PBS 0.025% Triton-X. The slides were then incubated in 3% hydrogen peroxide for 10 min, followed by three washes in PBS 0.025% Triton-X. For blocking, the slides were placed in a humidity chamber with 5% BSA in PBS for 1 h at RT. Following this, the CIP2A primary antibody (1:100, ab84547, Abcam) in 5% BSA was placed on the slides, in the humidity chamber and incubated overnight at 4 °C. The following day, the slides underwent three washes in PBS 0.025% Triton-X. Then an anti-rabbit secondary antibody (HRP008DAB-RB, Zytomed Systems, Oxfordshire, OX25 5HD, UK) was placed on the slides and incubated for 1 h at RT in a humidity chamber. The slides then underwent three washes in PBS 0.025% Triton-X. Streptavidin-HRP conjugate was added to the slides and incubated for 50 min at RT in the humidity chamber. Following this, the slides underwent washes in PBS 0.025% Triton-X. Then, the DAB solution was prepared and dispensed onto the slides for 10 min. This was followed by a counterstain with Harris' Haematoxylin. The slides then underwent dehydration through a series of washes in an increasing concentration of ethanol followed by 50:50 Histo-Clear and ethanol then Histo-Clear. The degree of staining of each stained core was scored from 0 to 4 as follows: 0 if < 10% stained, 1 if 10 to 25% stained, 2 if 25 to 30% stained, 3 if 50 to 75% stained and 4 if ≥ 75%. The scoring was repeated three times on three different days and performed by three lab members.

### Cell proliferation assays

A wound healing assay was performed as described by Sotiriadis et al.<sup>80</sup>. Immunofluorescence, cell viability and Annexin V/PI assays were performed following the protocols described by Saravi et al.<sup>81</sup>.

### Data availability

The datasets generated and/or analysed during the current study are available upon reasonable request. Researchers interested in accessing the data can contact the corresponding authors. Data on DEGs is provided within the supplementary information files.

Received: 1 November 2024; Accepted: 30 May 2025

Published online: 01 July 2025

### References

- Sung, H. et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **71**, 209–249. <https://doi.org/10.3322/caac.21660> (2021).
- Kossai, M., Leary, A., Scazecz, J. Y. & Genestie, C. Ovarian cancer: A heterogeneous disease. *Pathobiology* **85**, 41–49. <https://doi.org/10.1159/000479006> (2018).
- Asante, D. B., Calapre, L., Ziman, M., Meniawy, T. M. & Gray, E. S. Liquid biopsy in ovarian cancer using Circulating tumor DNA and cells: ready for prime time? *Cancer Lett.* **468**, 59–71. <https://doi.org/10.1016/j.canlet.2019.10.014> (2020).
- Stewart, C., Ralyea, C. & Lockwood, S. Ovarian cancer: an integrated review. *Semin Oncol. Nurs.* **35**, 151–156. <https://doi.org/10.1016/j.soncn.2019.02.001> (2019).
- Feeney, L., Harley, I. J., McCluggage, W. G., Mullan, P. B. & Beirne, J. P. Liquid biopsy in ovarian cancer: catching the silent killer before it strikes. *World J. Clin. Oncol.* **11**, 868–889. <https://doi.org/10.5306/wjco.v11.i11.868> (2020).
- Cramer, D. W. et al. CA125 immune complexes in ovarian cancer patients with low CA125 concentrations. *Clin. Chem.* **56**, 1889–1892. <https://doi.org/10.1373/clinchem.2010.153122> (2010).
- Kiely, M. & Kiely, P. A. PP2A: the Wolf in sheep's clothing?? *Cancers (Basel)*. **7**, 648–669. <https://doi.org/10.3390/cancers7020648> (2015).
- De, P., Carlson, J., Leyland-Jones, B. & Dey, N. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands. *Oncotarget* **5**, 4581–4602. <https://doi.org/10.18632/oncotarget.2127> (2014).
- Nvgelli, S. & Westermarck, J. CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response. *Trends Cancer*. **10**, 52–64. <https://doi.org/10.1016/j.trecan.2023.09.001> (2024).
- Consortium, G. The Genotype-Tissue expression (GTEx) project. *Nat. Genet.* **45**, 580–585. <https://doi.org/10.1038/ng.2653> (2013).
- Soofiyan, S. R., Hejazi, M. S. & Baradaran, B. The role of CIP2A in cancer: A review and update. *Biomed. Pharmacother.* **96**, 626–633. <https://doi.org/10.1016/j.biopha.2017.08.146> (2017).
- Côme, C. et al. CIP2A is associated with human breast cancer aggressivity. *Clin. Cancer Res.* **15**, 5092–5100. <https://doi.org/10.1158/1078-0432.Ccr-08-3283> (2009).
- Aslan, F., Güney, G., Avcıkurt, A. S., Taşkın, M. I. & Akgün, G. A. Relationship between CIP2A and endometrium Cancer. *J. Coll. Physicians Surg. Pak.* **30**, 373–378. <https://doi.org/10.29271/jcpsp.2020.04.373> (2020).
- Huang, L. P., Adelson, M. E., Mordechai, E. & Trama, J. P. CIP2A expression is elevated in cervical cancer. *Cancer Biomark.* **8**, 309–317. <https://doi.org/10.3233/cbm-2011-0220> (2010).
- Fang, Y., Li, Z., Wang, X. & Zhang, S. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis. *Tumour Biol.* **33**, 2299–2306. <https://doi.org/10.1007/s13277-012-0492-2> (2012).
- Cvriljevic, A. N. et al. Ovarian cancers with low CIP2A tumor expression constitute an APR-246-Sensitive disease subtype. *Mol. Cancer Ther.* **21**, 1236–1245. <https://doi.org/10.1158/1535-7163.Mct-21-0622> (2022).
- Tang, G., Cho, M. & Wang, X. OncoDB: an interactive online database for analysis of gene expression and viral infection in cancer. *Nucleic Acids Res.* **50**, D1334–d1339. <https://doi.org/10.1093/nar/gkab970> (2022).
- Laine, A. et al. CIP2A interacts with TopBP1 and drives Basal-Like breast Cancer tumorigenesis. *Cancer Res.* **81**, 4319–4331. <https://doi.org/10.1158/0008-5472.Can-20-3651> (2021).
- Laine, A. et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. *Cancer Discov.* **3**, 182–197. <https://doi.org/10.1158/2159-8290.Cd-12-0292> (2013).

20. Chandrashekar, D. S. et al. An update to the integrated cancer data analysis platform. *Neoplasia* **25**, UALCAN, 18–27. <https://doi.org/10.1016/j.neo.2022.01.001> (2022).
21. Chai, C. et al. Single-cell transcriptome analysis of epithelial, immune, and stromal signatures and interactions in human ovarian cancer. *Commun. Biol.* **7**, 131. <https://doi.org/10.1038/s42003-024-05826-1> (2024).
22. Xu, Z. et al. STOmicsDB: a comprehensive database for Spatial transcriptomics data sharing, analysis and visualization. *Nucleic Acids Res.* **52**, D1053–d1061. <https://doi.org/10.1093/nar/gkad933> (2024).
23. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* **2**, 401–404. <https://doi.org/10.1158/2159-8290.Cd-12-0095> (2012).
24. Ibitoye, O., Ibrahim, M. A. A. & Soliman, M. E. S. Exploring the composition of protein-ligand binding sites for cancerous inhibitor of PP2A (CIP2A) by inhibitor guided binding analysis: paving a new way for the discovery of drug candidates against triple negative breast cancer (TNBC). *J. Recept. Signal. Transduct. Res.* **43**, 133–143. <https://doi.org/10.1080/10799893.2023.2298903> (2023).
25. Lanczy, A. & Gyorffy, B. Web-Based survival analysis tool tailored for medical research (KMplot): development and implementation. *J. Med. Internet Res.* **23**, e27633. <https://doi.org/10.2196/27633> (2021).
26. Fekete, J. T. & Gyorffy, B. ROCplot.org: validating predictive biomarkers of chemotherapy/hormonal therapy/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients. *Int. J. Cancer.* **145**, 3140–3151. <https://doi.org/10.1002/ijc.32369> (2019).
27. Xu, F. et al. DbDEMC 3.0: functional exploration of differentially expressed MiRNAs in cancers of human and model organisms. *Genomics Proteom. Bioinf.* **20**, 446–454. <https://doi.org/10.1016/j.gpb.2022.04.006> (2022).
28. Subramanian, A. et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. *Cell* **171**, 1437–1452e1417. <https://doi.org/10.1016/j.cell.2017.10.049> (2017).
29. Akhmedov, M., Martinelli, A., Geiger, R. & Kwee, I. Omics playground: a comprehensive self-service platform for visualization, analytics and exploration of big omics data. *NAR Genom. Bioinform.* **2**, lqz019. <https://doi.org/10.1093/nargab/lqz019> (2020).
30. Kerslake, R. et al. Transcriptional landscape of 3D vs. 2D ovarian Cancer cell models. *Cancers (Basel)*. **15** <https://doi.org/10.3390/cancers15133350> (2023).
31. Kim, S. H. et al. The role of CIP2A as a therapeutic target of Rapamycin in radioresistant head and neck cancer with TP53 mutation. *Head Neck.* **41**, 3362–3371. <https://doi.org/10.1002/hed.25868> (2019).
32. Puustinen, P. et al. CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. *J. Cell. Biol.* **204**, 713–727. <https://doi.org/10.1083/jcb.201304012> (2014).
33. Bockelman, C. et al. Prognostic role of CIP2A expression in serous ovarian cancer. *Br. J. Cancer.* **105**, 989–995. <https://doi.org/10.1038/bjc.2011.346> (2011).
34. Ryland, G. L. et al. Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. *Genome Med.* **7**, 87. <https://doi.org/10.1186/s13073-015-0210-y> (2015).
35. Yang, C. A. et al. Whole exome sequencing in Dandy-Walker variant with intellectual disability reveals an activating CIP2A mutation as novel genetic cause. *Neurogenetics* **19**, 157–163. <https://doi.org/10.1007/s10048-018-0548-6> (2018).
36. Liu, Z. et al. Loss of function variant in CIP2A associated with female infertility with early embryonic arrest and fragmentation. *Biochim. Biophys. Acta Mol. Basis Dis.* **1870**, 167228. <https://doi.org/10.1016/j.bbdis.2024.167228> (2024).
37. Wang, T., Wang, X., Wu, J. & Li, X. Causal relationship between thyroid dysfunction and ovarian cancer: a two-sample Mendelian randomization study. *BMC Cancer.* **24**, 629. <https://doi.org/10.1186/s12885-024-12385-5> (2024).
38. Maccio, A. et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. *Blood* **106**, 362–367. <https://doi.org/10.1182/blood-2005-01-0160> (2005).
39. Wu, Y. et al. Hsa\_circ\_0001445 works as a cancer suppressor via miR-576-5p/SFRP1 axis regulation in ovarian cancer. *Cancer Med.* **12**, 5736–5750. <https://doi.org/10.1002/cam4.5317> (2023).
40. Valinezhad Orang, A., Safaralizadeh, R. & Kazemzadeh-Bavili, M. Mechanisms of miRNA-Mediated gene regulation from common downregulation to mRNA-Specific upregulation. *Int. J. Genomics.* **2014** (970607). <https://doi.org/10.1155/2014/970607> (2014).
41. Xu, J., Zhang, P., Sun, H. & Liu, Y. LINC01094/miR-577 axis regulates the progression of ovarian cancer. *J. Ovarian Res.* **13**, 122. <https://doi.org/10.1186/s13048-020-00721-9> (2020).
42. Zhang, S. & Wang, K. miR-383 Down-Regulates the oncogene CIP2A to influence glioma proliferation and invasion. *Onco Targets Ther.* **13**, 4063–4074. <https://doi.org/10.2147/ott.S248116> (2020).
43. Han, R. L., Wang, F. P., Zhang, P. A., Zhou, X. Y. & Li, Y. miR-383 inhibits ovarian cancer cell proliferation, invasion and aerobic Glycolysis by targeting LDHA. *Neoplasia* **64**, 244–252. [https://doi.org/10.4149/neo\\_2017\\_211](https://doi.org/10.4149/neo_2017_211) (2017).
44. Krasniqi, E. et al. MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a mirnomics study. *Biomark. Res.* **9**, 57. <https://doi.org/10.1186/s40364-021-00289-6> (2021).
45. Adam, S. et al. The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer. *Nat. Cancer.* **2**, 1357–1371. <https://doi.org/10.1038/s43018-021-00266-w> (2021).
46. Wang, C. Y. et al. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation. *Lung Cancer.* **85**, 152–160. <https://doi.org/10.1016/j.lungcan.2014.05.024> (2014).
47. Zeng, R. et al. OCT4 represses inflammation and cell injury during orchitis by regulating CIP2A expression. *Front. Cell. Dev. Biol.* **9**, 683209. <https://doi.org/10.3389/fcell.2021.683209> (2021).
48. Oien, D. B. & Chien, J. TP53 mutations as a biomarker for high-grade serous ovarian cancer: are we there yet? *Translational Cancer Res.* **S264**, S268 (2016).
49. Wang, Z. E. B. Receptors and Cancer. *Methods Mol. Biol.* **1652**, 3–35. [https://doi.org/10.1007/978-1-4939-7219-7\\_1](https://doi.org/10.1007/978-1-4939-7219-7_1) (2017).
50. Huntoon, C. J. et al. ATR Inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. *Cancer Res.* **73**, 3683–3691. <https://doi.org/10.1158/0008-5472.Can-13-0110> (2013).
51. Wang, M., Zhang, J. & Wu, Y. Tumor metabolism rewiring in epithelial ovarian cancer. *J. Ovarian Res.* **16** <https://doi.org/10.1186/s13048-023-01196-0> (2023).
52. Yang, J., Pi, C. & Wang, G. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. *Biomed. Pharmacother.* **103**, 699–707. <https://doi.org/10.1016/j.biopha.2018.04.072> (2018).
53. Khanna, A., Pimanda, J. E. & Westermarck, J. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. *Cancer Res.* **73**, 6548–6553. <https://doi.org/10.1158/0008-5472.Can-13-1994> (2013).
54. Sankpal, N. V. et al. Cancer-associated mutations reveal a novel role for EpCAM as an inhibitor of cathepsin-L and tumor cell invasion. *BMC Cancer.* **21**, 541. <https://doi.org/10.1186/s12885-021-08239-z> (2021).
55. Gires, O., Pan, M., Schinke, H., Canis, M. & Baeuerle, P. A. Expression and function of epithelial cell adhesion molecule epcam: where are we after 40 years? *Cancer Metastasis Rev.* **39**, 969–987. <https://doi.org/10.1007/s10555-020-09898-3> (2020).
56. Xu, J. et al. The anti-tumor effect of proteasome inhibitor MG132 for human adenoid cystic carcinoma: correlate with the emerging role of Nrf2/Keap1 signaling pathway. *Head Face Med.* **18** <https://doi.org/10.1186/s13005-022-00318-1> (2022).
57. Yakhni, M. et al. Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance. *Am. J. Cancer Res.* **9**, 1043–1060 (2019).
58. Cao, W. et al. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. *Sci. Rep.* **5**, 8477. <https://doi.org/10.1038/srep08477> (2015).
59. Zhu, M. et al. Homoharringtonine suppresses tumor proliferation and migration by regulating EphB4-mediated  $\beta$ -catenin loss in hepatocellular carcinoma. *Cell. Death Dis.* **11**, 632. <https://doi.org/10.1038/s41419-020-02902-2> (2020).

60. Cengiz Seval, G. & Beksac, M. The safety of bortezomib for the treatment of multiple myeloma. *Expert Opin. Drug Saf.* **17**, 953–962. <https://doi.org/10.1080/14740338.2018.1513487> (2018).
61. Avelar, R. A. et al. Small-Molecule-Mediated stabilization of PP2A modulates the homologous recombination pathway and potentiates DNA Damage-Induced cell death. *Mol. Cancer Ther.* **22**, 599–615. <https://doi.org/10.1158/1535-7163.Mct-21-0880> (2023).
62. Jumper, J. et al. Highly accurate protein structure prediction with alphafold. *Nature* **596**, 583–589. <https://doi.org/10.1038/s41586-021-03819-2> (2021).
63. Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. *J. Mol. Graph.* **14**, 33–38. [https://doi.org/10.1016/0263-7855\(96\)00018-5](https://doi.org/10.1016/0263-7855(96)00018-5) (1996).
64. Györfy, B. Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer. *Br. J. Pharmacol.* **181**, 362–374. <https://doi.org/10.1111/bph.16257> (2024).
65. Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779. <https://doi.org/10.1371/journal.pmed.1001779> (2015).
66. Saravi, S. et al. H2A histone family member X (H2AX) is upregulated in ovarian Cancer and demonstrates utility as a prognostic biomarker in terms of overall survival. *J. Clin. Med.* **9** <https://doi.org/10.3390/jcm9092844> (2020).
67. Mustafav, D., Siddiqui, S. S., Klena, L., Karteris, E. & Braoudaki, M. SV2B/miR-34a/miR-128 axis as prognostic biomarker in glioblastoma multiforme. *Sci. Rep.* **14**, 6647. <https://doi.org/10.1038/s41598-024-55917-6> (2024).
68. Chen, Y. & Wang, X. MiRDB: an online database for prediction of functional MicroRNA targets. *Nucleic Acids Res.* **48**, D127–d131. <https://doi.org/10.1093/nar/gkz757> (2020).
69. Agarwal, V., Bell, G. W., Nam, J. W. & Bartel, D. P. Predicting effective MicroRNA target sites in mammalian mRNAs. *Elife* **4** <https://doi.org/10.7554/eLife.05005> (2015).
70. Lu, T. P. et al. MiRSystem: an integrated system for characterizing enriched functions and pathways of MicroRNA targets. *PLoS One.* **7**, e42390. <https://doi.org/10.1371/journal.pone.0042390> (2012).
71. Li, J. H., Liu, S., Zhou, H., Qu, L. H. & Yang, J. H. StarBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. *Nucleic Acids Res.* **42**, D92–97. <https://doi.org/10.1093/nar/gkt1248> (2014).
72. Oliveros, J. C. An interactive tool for comparing lists with Venn's diagrams. *Scientific researcher* (2015).
73. Kozomara, A., Birgaoanu, M. & Griffiths-Jones, S. MiRBase: from MicroRNA sequences to function. *Nucleic Acids Res.* **47**, D155–d162. <https://doi.org/10.1093/nar/gky1141> (2019).
74. Rennie, W. et al. STarMirDB: A database of MicroRNA binding sites. *RNA Biol.* **13**, 554–560. <https://doi.org/10.1080/15476286.2016.1182279> (2016).
75. Szklarczyk, D. et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res.* **51**, D638–d646. <https://doi.org/10.1093/nar/gkac1000> (2023).
76. Chang, L. & Xia, J. MicroRNA regulatory network analysis using MiRNet 2.0. *Methods Mol. Biol.* **2594**, 185–204. [https://doi.org/10.1007/978-1-0716-2815-7\\_14](https://doi.org/10.1007/978-1-0716-2815-7_14) (2023).
77. Kerslake, R. et al. Differential regulation of genes by the glucogenic hormone Asprosin in ovarian Cancer. *J. Clin. Med.* **11** <https://doi.org/10.3390/jcm11195942> (2022).
78. Pathan, M. et al. A novel community driven software for functional enrichment analysis of extracellular vesicles data. *J. Extracell. Vesicles.* **6**, 1321455. <https://doi.org/10.1080/20013078.2017.1321455> (2017).
79. Filipe, A. et al. Differential expression of RAD51AP1 in ovarian cancer: effects of SiRNA in vitro. *J. Pers. Med.* **12** <https://doi.org/10.3390/jpm12020201> (2022).
80. Sotiriadis, G. et al. Surfactant proteins SP-A and SP-D modulate uterine contractile events in ULTR myometrial cell line. *PLoS One.* **10**, e0143379. <https://doi.org/10.1371/journal.pone.0143379> (2015).
81. Saravi, S., Alizzi, Z., Tosi, S., Hall, M. & Karteris, E. Preclinical studies on the effect of Rucaparib in ovarian cancer: impact of BRCA2 status. *Cells* **10** <https://doi.org/10.3390/cells10092434> (2021).

## Acknowledgements

We would like to thank Professor Jukka Westermarck, University of Turku, Finland for all his useful discussions during this project and for editing the final version of the manuscript.

## Author contributions

AF, DM, SP, SB, SS, SP, SM, MAS, FD, SK have generated the data. AF, MAS, SK, CS, EK, DM prepared Figs. 1, 2, 3, 4, 5 and 6. DM, MB prepared Table 1, and 2. MB, YR, EK were responsible for the supervision. AF and EK wrote the main manuscript. AF, EK, SS, YR, FD, CS, EK edited the final version prior to submission. All authors reviewed the manuscript. AF and SS should be considered as joint first authors.

## Declarations

## Competing interests

The authors declare no competing interests.

## Additional information

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1038/s41598-025-05013-0>.

**Correspondence** and requests for materials should be addressed to E.K.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2025